US FDA orders new eye risk warnings for Ozempic, Zepbound - CNN
US FDA orders new eye risk warnings for Ozempic, Zepbound CNN
US FDA orders new eye risk warnings for Ozempic, Zepbound CNN
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound CNBC
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors The Globe and Mail
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo Fierce Biotech
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity PR Newswire
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial STAT
GLP-1 drugs reduce hospitalizations, but the math still doesn’t work for employers NewsNation
Zepbound Lowered Teens' BMI 18.5% to 21.4% in 72-Week Trial, but Most Had Stomach Side Effects Medical Daily
Stopping Wegovy or Zepbound? How to Keep Weight Off Healthline
Lilly’s Obesity Drug Zepbound Helped Adolescents Lose Weight Bloomberg.com
What is Zepbound? Does this weight-loss drug work better than Wegovy and Ozempic? UCHealth
Eli Lilly study aims to bolster case for long-term Zepbound benefits Fierce Healthcare
Editorial: GLP-1s and the limits of postnormal science Chemical & Engineering News
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale PR Newswire
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns Fox News
Eli Lilly CEO David Ricks Is Using the Weight-Loss Boom to Buy His Next Bet Observer
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity Eli Lilly
Health Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure WKZO
Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat ScienceDaily
GLP-1 compounder issues recall for copycat Zepbound BioPharma Dive
Zepbound And Foundayo Are Coming To Hims & Hers: What Patients Should Know Blavity News
Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight The Globe and Mail
Lilly's Zepbound remains physicians' favorite, even as oral obesity launches alter landscape Fierce Pharma
FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound Fierce Pharma
Lilly’s Zepbound shows promise in teen obesity trial (LLY:NYSE) Seeking Alpha
Eli Lilly’s $1.4 trln valuation is heavy with hope Breakingviews
GLP-1s Now Carry a Warning About a Rare Vision-Threatening Eye Condition | Newswise Newswise
On a GLP-1 This Holiday? How to Enjoy the Big Feast Without Side Effects U.S. News & World Report
Tirzepatide (Zepbound) for the Treatment of Obesity American Academy Of Family Physicians | AAFP
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity Eli Lilly
Medicare and Weight-Loss Drugs: Coverage Expansion in 2026 GoodRx
New Drug Combo With Zepbound Leads to Massive Weight Loss Yahoo Health
2 Patients Have Been Hospitalized With Psychosis or Mania After Abruptly Stopping GLP-1s ScienceAlert
Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects? The Globe and Mail
Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen Publix
Here’s what’s been proven to help GLP-1 users from losing too much muscle from the drug MarketWatch
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study Eli Lilly
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison Eli Lilly